The C3 inhibitor (APL) developed by Apellis Pharmaceuticals, Inc., and the C5 inhibitor (Zimura) developed by the Original Ophtothtech Corporation (NCT 02686658) prove that the complement system has potential application prospects as a drug target for the treatment of AMD. The gene discussed is C3; the disease is age-related macular degeneration.